Zika Virus Research

Zika fever represents a mosquito-borne viral disease caused by Zika virus that has circulated in Africa and Southeast Asia but has recently spread through Latin America and the South Pacific. In November 2015, preliminary evidence suggested a potential association with an upsurge in neurological complications in adults (most notable Guillain-Barré syndrome) and microcephaly in neonates of mothers infected during pregnancy.

zika virusImage Credit: Kateryna Kon/Shutterstock.com

Facts about Zika virus

Zika virus belongs to a group of RNA viruses and contains 10,794 nucleotides that encode 3,419 amino acids. Together with its close relative Spondweni virus, Zika virus forms a specific group within mosquito-borne flaviviruses, with the next nearest relative being the St. Louis encephalitis virus.

Even though flaviviruses replicate predominantly in cellular cytoplasm, Zika virus antigens can also be detected in nuclei of the infected cell. Infectious viral particles can be detected in human blood from the onset of illness, whereas viral RNA can be found even 11 days after onset.

While it is not effectively neutralized with 10% ethanol, Zika virus can be killed by ether, potassium permanganate, as well as by temperatures over 60 °C. Diagnostic techniques for Zika virus detection include PCR testing of acute-phase serum samples in order to detect viral RNA, but also other tests that screen for specific antibodies against the virus.

Growing research interest

Although Zika virus was only recently introduced to the Western Hemisphere, its relatives (such as dengue and West Nile virus) have been studied for a long time, providing a springboard that should accelerate Zika virus research and may result in novel approaches for the development of treatment options and vaccines.

In 2016, the US National Institute of Allergy and Infectious Diseases highlighted its interest in sponsoring research on Zika virus that would concentrate on developing sensitive and specific diagnostic tests, performing surveillance studies, developing animal models that could successfully mimic Zika infection in people, as well as identifying factors that influence virulence and host-range.

In response to the dramatic increase of microcephaly and Guillain-Barré syndrome across Latin America linked to the Zika virus, the European Commission decided to mobilize 10 million Euros for additional research that would result in improved diagnostic techniques and potential treatments.

Furthermore, PREPARE (Platform for European Preparedness Against (Re-) emerging Epidemics) joined forces with ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) in their endeavor to create standardized Zika virus research tools that would aid in collecting clinical and laboratory data from individuals infected with the virus.

Zika Virus 101

Treatment and vaccine research

Several vaccine platforms are currently investigated by different research groups. A DNA-based vaccine developed by researchers at the US National Institute of Allergy and Infectious Diseases employs a strategy comparable to an experimental flavivirus vaccine developed for the West Nile virus. This vaccine successfully induced immune response in a phase I clinical trial and was found to be safe.

Dengue virus vaccine also served as a template for the development of live attenuated Zika vaccine, whereas the approach with genetically engineered vesicular stomatitis virus (which yielded some success against Ebola) is at the early stage, waiting for experiments in both tissue culture and animal models.

US National Institute of Allergy and Infectious Diseases also employed the existing antiviral screening program for other flaviviruses (such as yellow fever and West Nile virus) in order to create a test for examination of compounds with potential activity against Zika virus. The end goal is to develop an antiviral drug with a broad spectrum that could be used in the treatment of different flaviviruses – including Zika virus.


Further Reading

Last Updated: Dec 23, 2022

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2022, December 23). Zika Virus Research. News-Medical. Retrieved on February 28, 2024 from https://www.news-medical.net/health/Zika-Virus-Research.aspx.

  • MLA

    Meštrović, Tomislav. "Zika Virus Research". News-Medical. 28 February 2024. <https://www.news-medical.net/health/Zika-Virus-Research.aspx>.

  • Chicago

    Meštrović, Tomislav. "Zika Virus Research". News-Medical. https://www.news-medical.net/health/Zika-Virus-Research.aspx. (accessed February 28, 2024).

  • Harvard

    Meštrović, Tomislav. 2022. Zika Virus Research. News-Medical, viewed 28 February 2024, https://www.news-medical.net/health/Zika-Virus-Research.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Zika virus effective in eliminating neuroblastoma tumors in mice, study finds